(13S)-13-(5-chlorofuran-2-yl)-8-[4-[(1S)-1-hydroxyethyl]-1,3-thiazol-2-yl]-3,5-dimethyl-12-thia-3,5,9-triazatricyclo[7.4.0.02,7]trideca-1,7-diene-4,6-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (13S)-13-(5-chlorofuran-2-yl)-8-[4-[(1S)-1-hydroxyethyl]-1,3-thiazol-2-yl]-3,5-dimethyl-12-thia-3,5,9-triazatricyclo[7.4.0.02,7]trideca-1,7-diene-4,6-dione
• 化学式: C₂₀H₁₉ClN₄O₄S₂
• 分子量: 479.0
• InChiKey: LZVAAXNDLUJMFY-HUTHGQBESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  31
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  145
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• TRICYCLIC COMPOUNDS
  申请人：AHMED Mahbub

  公开号：US20140171417A1

  公开（公告）日：2014-06-19

  The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种式I的化合物或其药学上可接受的盐；以及其治疗用途。本发明还提供了一种药理活性剂的组合和一种药物组合物。
• TRICYCLIC COMPOUNDS FOR INHIBITING THE CFTR CHANNEL
  申请人：AHMED Mahbub

  公开号：US20150336986A1

  公开（公告）日：2015-11-26

  The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了I式化合物或其药学上可接受的盐；以及其治疗用途。本发明还提供了一种药理活性剂的组合和制药组合物。
• NOVEL DOUBLE-STRANDED RIBONUCLEIC ACIDS WITH RUGGED PHYSICO-CHEMICAL STRUCTURE AND HIGHLY SPECIFIC BIOLOGIC ACTIVITY
  申请人：CARTER William A.

  公开号：US20140170191A1

  公开（公告）日：2014-06-19

  A novel form of Rugged dsRNA with a unique composition and physical characteristics was identified with high specificity of binding to TLR3, which conveys an important range of therapeutic opportunities. Unlike the previous known antiviral Ampligen® (poly I, poly C12,U) the new and improved form (poly I, poly C 30 ,U) has a reduced tendency to form branched dsRNA which results in increased bioactivity due to an increased ability to bind TLR3 receptor. Pharmaceutical formulations containing the new nucleic acid as active ingredients and methods of treatment are also provided. The invention also provides a description of the physicochemical properties of this novel form of Rugged dsRNA and a method for its preparation in substantially pure form. DsRNAs acting thru TLR3 receptor activation are potent antiviral compounds as well as anticancer agents; also through secondary immunomodulation they can enhance the bioactivity of vaccines and also treat autoimmune disorders.
• US9359381B2
  申请人：——

  公开号：US9359381B2

  公开（公告）日：2016-06-07